Business Description
Palisade Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US6963894026
Total Employee Number:
14Description
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1762.99 | |||||
Equity-to-Asset | 0.96 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 37.07 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 89.2 | |||||
3-Year EPS without NRI Growth Rate | 88.9 | |||||
3-Year FCF Growth Rate | 90.5 | |||||
3-Year Book Growth Rate | -70.5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.87 | |||||
9-Day RSI | 49.98 | |||||
14-Day RSI | 50.34 | |||||
3-1 Month Momentum % | 20.22 | |||||
6-1 Month Momentum % | 7 | |||||
12-1 Month Momentum % | 267.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 24.26 | |||||
Quick Ratio | 24.26 | |||||
Cash Ratio | 23.86 | |||||
Days Sales Outstanding | 365 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -638.7 | |||||
Shareholder Yield % | -0.89 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -7069.8 | |||||
Net Margin % | -6388.2 | |||||
EBITDA Margin % | -6386.4 | |||||
FCF Margin % | -3638 | |||||
OCF Margin % | -3638 | |||||
ROE % | -41.55 | |||||
ROA % | -39.08 | |||||
ROIC % | -4357.62 | |||||
3-Year ROIIC % | 3267.86 | |||||
ROC (Joel Greenblatt) % | -81879.49 | |||||
ROCE % | -41.4 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1027.5 | |||||
PB Ratio | 2.93 | |||||
Price-to-Tangible-Book | 2.94 | |||||
EV-to-EBIT | -7.05 | |||||
EV-to-Forward-EBIT | -9.79 | |||||
EV-to-EBITDA | -7.05 | |||||
EV-to-Revenue | 450.45 | |||||
EV-to-Forward-Revenue | 0.76 | |||||
EV-to-FCF | -12.38 | |||||
| Price-to-Net-Current-Asset-Value | 2.94 | |||||
| Price-to-Net-Cash | 2.98 | |||||
Earnings Yield (Greenblatt) % | -14.18 | |||||
FCF Yield % | -5.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PALI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Palisade Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.5 | ||
| EPS (TTM) ($) | -0.536 | ||
| Beta | 1.2454 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.33 | ||
| Volatility % | 148.36 | ||
| 14-Day RSI | 50.34 | ||
| 14-Day ATR ($) | 0.112002 | ||
| 20-Day SMA ($) | 2.066 | ||
| 12-1 Month Momentum % | 267.7 | ||
| 52-Week Range ($) | 0.54651 - 2.855 | ||
| Shares Outstanding (Mil) | 174.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Palisade Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Palisade Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 59 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-16 10:00 | In 5 days | ||
| Analyst meeting for 2026 | 2026-09-08 | 2.09 (+2.96%) | ||
| Second quarter earnings results for 2026 | 2026-08-10 | 2.11 (+1.44%) | ||
| General meeting for 2026 | 2026-06-10 10:00 | 1.69 (-3.43%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 15:45 | 1.93 (+2.66%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 1.94 (+7.18%) | ||
| e Needham & Co. 25th Annual Healthcare Conference | 2026-04-16 14:15 | 2.34 (+11.96%) | ||
| Palisade Bio Update Conference Call | 2026-03-31 08:00 | 1.78 (-8.72%) | ||
| Annual report for 2025 | 2026-03-24 | 1.91 (+0.00%) |
Show
Entries
Palisade Bio Inc Frequently Asked Questions
What is Palisade Bio Inc(PALI)'s stock price today?
The current price of PALI is $2.06. The 52 week high of PALI is $2.86 and 52 week low is $0.55.
When is next earnings date of Palisade Bio Inc(PALI)?
The next earnings date of Palisade Bio Inc(PALI) is 2026-11-10 Est..
Does Palisade Bio Inc(PALI) pay dividends? If so, how much?
Palisade Bio Inc(PALI) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Palisade Bio, Inc. (NASDAQ: PALI) | 2025-10-20 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers